The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P. SkarbnikAmanda F. Cashen, David T. Weaver, Virginia M. Kelly, Barry Turnbull, Stephan Stilgenbauer

Research output: Contribution to journalArticlepeer-review

171 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds